83 related articles for article (PubMed ID: 17477790)
21. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
22. Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy.
Holysz M; Bialas K; Migdalski P; Kmieciak D; Trzeciak WH
J Appl Genet; 2015 Aug; 56(3):403-9. PubMed ID: 25588648
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
24. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
25. Management of hepatitis C.
Teo M; Hayes P
Br Med Bull; 2004; 70():51-69. PubMed ID: 15466491
[TBL] [Abstract][Full Text] [Related]
26. Viral determinants of resistance to treatment in patients with hepatitis C.
Wohnsland A; Hofmann WP; Sarrazin C
Clin Microbiol Rev; 2007 Jan; 20(1):23-38. PubMed ID: 17223621
[TBL] [Abstract][Full Text] [Related]
27. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
28. Mutations in the STAT1‑interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy.
Anjum S; Afzal MS; Ahmad T; Aslam B; Waheed Y; Shafi T; Qadri I
Mol Med Rep; 2013 Aug; 8(2):487-92. PubMed ID: 23799612
[TBL] [Abstract][Full Text] [Related]
29. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Michielsen P; Ho E; Francque S
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
[TBL] [Abstract][Full Text] [Related]
30. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
Xu J; Liu S; Xu Y; Tien P; Gao G
Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
[TBL] [Abstract][Full Text] [Related]
31. Mutation-prone positions within the estrogen receptor.
Wiwanitkit V
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):130-2. PubMed ID: 19574173
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
[TBL] [Abstract][Full Text] [Related]
33. The eradication of HCV.
De Nicola S; Colombo M
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):63-75. PubMed ID: 26446686
[TBL] [Abstract][Full Text] [Related]
34. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
[TBL] [Abstract][Full Text] [Related]
35. Prevention of hepatitis C virus infection and liver cancer.
Lim EJ; Torresi J
Recent Results Cancer Res; 2014; 193():113-33. PubMed ID: 24008296
[TBL] [Abstract][Full Text] [Related]
36. Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report.
Tomova R; Antonov K; Ivanova A; Jacobs JJ; Koten JW; Den Otter W; Krastev Z
Anticancer Res; 2009 Dec; 29(12):5241-4. PubMed ID: 20044643
[TBL] [Abstract][Full Text] [Related]
37. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
[TBL] [Abstract][Full Text] [Related]
38. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
[TBL] [Abstract][Full Text] [Related]
39. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
[TBL] [Abstract][Full Text] [Related]
40. Resistance to direct antiviral agents in patients with hepatitis C virus infection.
Sarrazin C; Zeuzem S
Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
